Article

2016 Prostate Cancer Conference

Author(s):

PCRI

"The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community."

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

This September 9-11, 2016, interact with practicing physicians and leading researchers to get your prostate cancer questions answered in multiple Q+A and breakout sessions! Topics cover everything from treatment options to side effect management. You will also glean from the experiences of your fellow patients and caregivers in support groups, dinners, and excursions. You will find empowering information that is relative to your case. We look forward to seeing you in September!

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

The Prostate Cancer Research Institute, (PCRI), a 501(c)(3) not-for-profit organization, mission is to improve the quality of prostate cancer patients and caregivers lives by supporting research and disseminating information that educates and empowers patients, families and the medical community.

Learn more here >>

Related Videos
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of man with brown and grey hair.
Dr. Kelly Stratton
Reginald Tucker-Seeley, MA, ScM, ScD, an expert on prostate cancer
Alicia Morgans, MD, MPH, an expert on prostate cancer
Related Content
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
February 16th 2025

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

Roman Fabbricatore
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
"Prostate cancer" text.
February 14th 2025

Estrogen Patches with ARPIs Found to Be Safe, Effective in Prostate Cancer

Alex Biese
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone analogues and ARPIs among patients with metastatic prostate cancer.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. | © pikovit - stock.adobe.com
February 13th 2025

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

Alex Biese
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.
Illustration of body highlighting prostate area.
February 13th 2025

Elevated PSA Link to Higher Recurrence Risk in Intermediate-Risk Prostate Cancer

Ryan Scott
Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall recurrence and treatment failure.